Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness
Clinical trial NCT05303376 · COMPLETED
Trial details
- NCT number
- NCT05303376
- Sponsor
- Immune Biosolutions Inc
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-22
- Primary completion
- 2023-06-27
- Enrollment
- 123
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.